MedTrace Logo

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

NCT06777628 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-01-16

No results posted yet for this study

Summary

The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for:

* predicting response to immune-therapeutic regimens in HCC in the early phase of treatment,
* to rule out pseudo-progression,
* to early predict the escape from effectiveness of treatment.

Conditions

  • Liver Cancer, Adult

Interventions

DRUG

Immunochemotherapy combined with antiangiogenic

Immunochemotherapy combined with antiangiogenic

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Laura Gramantieri · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-15
Primary Completion
2026-10-15
Completion
2028-10-15

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06777628 on ClinicalTrials.gov